Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sekur Private Data Advances Defense-Grade Secure Communications Platform (click to learn more) Sorrento Resources Ltd. Intersects 33m of 2.12% TREO, Bottom Brook, Newfoundland (click to learn more) Explore the Innovation Trends Shaping Tomorrow’s Investment Landscape (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Wellbeing Digital Sciences Inc (EM) KONEF

Healthcare Psychedelics
Wellbeing Digital Sciences Inc., a next generation wellness company, focuses on ketamine assisted therapy and psychedelic medicines through operating healthcare clinics in North America. The company was formerly known as KetamineOne Capital Limited and changed its name to Wellbeing Digital Sciences Inc. in January 2022. Wellbeing Digital Sciences Inc. was founded in 2017 and is headquartered in... see more

Recent & Breaking News (EXPM:KONEF)

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference

Business Wire June 19, 2023

Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group

Business Wire June 16, 2023

Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference

Business Wire May 25, 2023

Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response

Business Wire May 3, 2023

Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial

Business Wire April 18, 2023

Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval

Business Wire April 11, 2023

Wellbeing Announces Cease Trade Order

Business Wire April 6, 2023

IIROC Trading Halt - MEDI

Canada NewsWire April 6, 2023

Wellbeing Provides Bi-Weekly Default Status Report

Business Wire March 16, 2023

Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference

Business Wire March 16, 2023

Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion

Business Wire March 13, 2023

Wellbeing Digital to Participate in The Global Biomedical Design Conference

Business Wire March 9, 2023

Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout

Business Wire March 8, 2023

Wellbeing Provides Bi-Weekly Default Status Report

Business Wire March 2, 2023

Wellbeing Digital to Participate in MarigoldLIVE: International Women's Day Networking Event

Business Wire March 1, 2023

Wellbeing Provides Bi-Weekly Default Status Report

Business Wire February 16, 2023

Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.

Business Wire February 15, 2023

Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial

Business Wire February 14, 2023

Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order

Business Wire February 1, 2023

Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

Business Wire January 25, 2023

Podcasts